122 related articles for article (PubMed ID: 21305270)
1. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
Makras P; Anastasilakis AD; Polyzos SA; Bisbinas I; Sakellariou GT; Papapoulos SE
Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
[TBL] [Abstract][Full Text] [Related]
2. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
[TBL] [Abstract][Full Text] [Related]
3. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Delaroudis S; Bisbinas I; Sakellariou GT; Gkiomisi A; Papadopoulou E; Gerou S; Makras P
Clin Endocrinol (Oxf); 2012 Dec; 77(6):816-22. PubMed ID: 22676573
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
5. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
7. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
[TBL] [Abstract][Full Text] [Related]
8. Characterization of and risk factors for the acute-phase response after zoledronic acid.
Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
Catalano A; Morabito N; Atteritano M; Basile G; Cucinotta D; Lasco A
Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
[TBL] [Abstract][Full Text] [Related]
10. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
[TBL] [Abstract][Full Text] [Related]
11. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
[TBL] [Abstract][Full Text] [Related]
13. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
Kassi G; Papamichael K; Papaioannou G; Giagourta I; Thanou S; Triantaphyllopoulou M; Zapanti E; Papandroulaki F; Ktena V; Karga H
Immunol Invest; 2014; 43(6):544-55. PubMed ID: 24661204
[TBL] [Abstract][Full Text] [Related]
14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
15. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion.
Srivastava T; Haney CJ; Alon US
J Bone Miner Res; 2009 Feb; 24(2):334-7. PubMed ID: 18847329
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Burmeister JE; Miltersteiner DR; Campos BM
J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin in older patients with systolic heart failure.
Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
[TBL] [Abstract][Full Text] [Related]
20. Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.
Rossini M; Adami S; Viapiana O; Tripi G; Zanotti R; Ortolani R; Vella A; Troplini S; Gatti D
Calcif Tissue Int; 2013 Sep; 93(3):249-52. PubMed ID: 23748711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
